Immunic, Inc. to Showcase Research at Upcoming Conferences

Immunic, Inc. to Participate in Major Conferences

Immunic, Inc. (Nasdaq: IMUX), a pioneering biotechnology firm focused on developing small molecule therapies aimed at chronic inflammatory and autoimmune diseases, recently shared its schedule for participation in significant investor and scientific conferences during September. This showcases the company's commitment to advancing its innovative treatment solutions.

Upcoming Conferences and Presentations

During the month of September, Immunic is set to feature its latest developments at the following notable conferences:

• H.C. Wainwright 27th Annual Global Investment Conference - September 8-10

Jason Tardio, President and COO of Immunic, will deliver an overview of the company. Interested parties may access the on-demand presentation starting September 5 at 7:00 AM ET via the H.C. Wainwright Conference Portal. Tardio, along with Daniel Vitt, Ph.D., CEO, and Jessica Breu, VP of Investor Relations, will also hold one-on-one meetings with investors at the conference in New York. For meeting scheduling details, participants can visit the conference website.

• 2025 Leerink Partners Biopharma Summit - September 17-19

Here, Dr. Vitt will engage in discussions around the company’s advancements and future directions.

• 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - September 24-26

Members from the various Immunic teams, including management and medical staff, will showcase the company's contributions at this vital conference. Key data regarding their innovative asset, vidofludimus calcium (IMU-838), will be communicated through oral and poster presentations, further highlighting Immunic’s role in advancing therapeutic understanding in multiple sclerosis.

Key Presentation Details at ECTRIMS

At ECTRIMS, Immunic will present data from important studies:

• Oral Presentation: Efficacy and Safety of Vidofludimus Calcium, a Novel Nurr1 Activator and Selective DHODH Inhibitor, in Progressive Multiple Sclerosis: Data from the Phase 2 CALLIPER Trial
• Presenting Author: Robert J. Fox, M.D., from the Cleveland Clinic, will lead this session.
• Abstract Number: ECTRIMS25-1404
• Session Details: This presentation is scheduled for September 24 at 2:35 PM CEST.

Late Breaking and Poster Presentations

In addition to the oral sessions, Immunic will feature late-breaking posters covering vital research:

• Poster Presentation: Efficacy and Safety of Vidofludimus Calcium in Primary Progressive Multiple Sclerosis: Phase 2 CALLIPER Trial
• Abstract Number: IMS25-LBA-317
• Time: Scheduled for September 24 from 4:30-6:30 PM CEST.

Innovations by Immunic, Inc.

Immunic, Inc. stands at the forefront of biotechnology, channeling efforts into their lead product vidofludimus calcium (IMU-838). Presently in phase 3 clinical trials for relapsing multiple sclerosis, this innovative drug is distinguished by its dual mechanism of action: acting as a nuclear receptor-related 1 (Nurr1) activator while also inhibiting dihydroorotate dehydrogenase (DHODH). As a result, it not only displays neuroprotective capabilities but also anti-viral and anti-inflammatory properties, establishing itself as a significant advancement in therapeutic strategies.

Moreover, developing therapies such as IMU-856, targeting Sirtuin 6 (SIRT6), seeks to enhance intestinal barrier function, which holds promise for gastrointestinal diseases such as celiac disease and inflammatory bowel diseases. Another exciting molecule, IMU-381, is currently in preclinical evaluation and aims to cater specifically to gastrointestinal disorders.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is committed to developing a pipeline of innovative orally administered small molecule therapies tackling chronic inflammatory and autoimmune diseases. With a firm foothold in the clinical landscape, the company anticipates crucial top-line data from its lead program by the end of 2026. For more detailed insights, interested parties may visit the company’s website.

Frequently Asked Questions

What events will Immunic, Inc. participate in during September?

Immunic, Inc. will participate in the H.C. Wainwright Conference, the Leerink Partners Biopharma Summit, and the ECTRIMS conference.

What is Immunic’s lead product?

The lead product is vidofludimus calcium (IMU-838), which focuses on treating relapsing multiple sclerosis.

Where can I find detailed research presentations from Immunic?

All presentations will be available on Immunic's website under the 'Events and Presentations' section following the conferences.

Who will present at the ECTRIMS conference?

Robert J. Fox, M.D., will present crucial data regarding vidofludimus calcium’s efficacy and safety.

What role does SIRT6 play in Immunic’s developmental pipeline?

SIRT6 is targeted by IMU-856, which aims to restore intestinal function and address various gastrointestinal disorders.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.